Hemophilia Research Today is a free monthly online journal that collates and summarizes the latest research about Hemophilia, including details on genetics, causes, symptoms, blood transfusion.

Volume 7 (2011), Issue 6 (June)

1. Up-regulation of platelet activation in hemophilia A.
   Haematologica, 96(6): 888-95. [Abstract] [Full-text]
2. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
   Biochem Pharmacol, 82(2): 91-8. [Abstract] [Full-text]
3. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.
   Blood, 117(23): 6367-70. [Abstract] [Full-text]
4. International comparative field study of N8 evaluating factor VIII assay performance.
   Haemophilia, 17(4): 695-702. [Abstract] [Full-text]
5. The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity.
   Haemophilia, 17(4): 689-94. [Abstract] [Full-text]
6. Assessment of musculoskeletal function and mood in haemophilia A adolescents: a cross-sectional study.
   Haemophilia, 17(4): 683-8. [Abstract] [Full-text]
7. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A.
   Haemophilia, 17(4): 641-9. [Abstract] [Full-text]
8. Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.
   Haemophilia, 17(4): 571-8. [Abstract] [Full-text]
9. Assessment of acute and persistent pain management in patients with haemophilia.
   Haemophilia, 17(4): 612-9. [Abstract] [Full-text]
10. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
    Haemophilia, 17(4): 630-5. [Abstract] [Full-text]
11. SEMG activation patterns of thigh muscles during upright standing in haemophilic patients.
    Haemophilia, 17(4): 669-75. [Abstract] [Full-text]
12. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US).
    Haemophilia, 17(4): 597-604. [Abstract] [Full-text]
13. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Haemophilia, 17(4): 650-6. [Abstract] [Full-text]
14. The Swedish version of the Haemophilia Activity List.
    Haemophilia, 17(4): 662-8. [Abstract] [Full-text]
15. Comparison of physical activity and sedentary behaviours between young haemophilia A patients and healthy adolescents.
    Haemophilia, 17(4): 676-82. [Abstract] [Full-text]
16. Alloantibodies to factor VIII in haemophilia.
    Haemophilia, 17(4): 636-40. [Abstract] [Full-text]
17. A patient-prioritized ability assessment in haemophilia: the Canadian Occupational Performance Measure.
    Haemophilia, 17(4): 605-11. [Abstract] [Full-text]
18. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Haemophilia, 17(4): 625-9. [Abstract] [Full-text]
19. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Haemophilia, 17(4): 579-89. [Abstract] [Full-text]
20. Bone turnover markers and bone mineral density in children with haemophilia.
    Haemophilia, 17(4): 657-61. [Abstract] [Full-text]
21. Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis.
    Clin Rheumatol, 30(7): 915-9. [Abstract] [Full-text]

© 2005-2011 Hemophilia Research Today. All Rights Reserved.